Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H20N2O.ClH |
| Molecular Weight | 256.772 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCNC(C)C(=O)NC1=CC=CC=C1C
InChI
InChIKey=BJPJNTKRKALCPP-UHFFFAOYSA-N
InChI=1S/C13H20N2O.ClH/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2;/h5-8,11,14H,4,9H2,1-3H3,(H,15,16);1H
| Molecular Formula | C13H20N2O |
| Molecular Weight | 220.3107 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00750
Sources: http://www.drugbank.ca/drugs/DB00750
Prilocaine is a local anesthetic that is similar pharmacologically to lidocaine. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns. Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Currently, Prilocaine is used most often for infiltration anesthesia in dentistry.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:1903409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11421833 |
|||
Target ID: CHEMBL1980 Sources: http://www.drugbank.ca/drugs/DB00750 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | ORAQIX Approved UseOraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. Launch Date2003 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
106 ng/mL |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.07 μg/mL |
1.5 g single, topical dose: 1.5 g route of administration: Topical experiment type: SINGLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
26000 ng × min/mL |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.8 h |
42.5 mg 5 times / 3 hours multiple, buccal dose: 42.5 mg route of administration: Buccal experiment type: MULTIPLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
70 min |
single, intravenous |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
45% |
1.5 g single, topical dose: 1.5 g route of administration: Topical experiment type: SINGLE co-administered: LIDOCAINE |
PRILOCAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
6 mg/kg single, transdermal Dose: 6 mg/kg Route: transdermal Route: single Dose: 6 mg/kg Sources: |
unhealthy, 6 years |
Other AEs: Methemoglobinemia... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Methemoglobinemia | 6 mg/kg single, transdermal Dose: 6 mg/kg Route: transdermal Route: single Dose: 6 mg/kg Sources: |
unhealthy, 6 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Use of EMLA cream with vasectomy. | 2002-07 |
|
| The use of glyceryl trinitrate ointment with EMLA cream for i.v. cannulation in children undergoing routine surgery. | 2002-06 |
|
| A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. | 2002-06 |
|
| Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children. | 2002-06 |
|
| Amethocaine-lidocaine cream, a new topical formulation for preventing venopuncture-induced pain in children. | 2002-05-23 |
|
| In vitro effects of some anesthetic drugs on enzymatic activity of human red blood cell glucose 6-phosphate dehydrogenase. | 2002-05-22 |
|
| Reducing venipuncture and intravenous insertion pain with eutectic mixture of local anesthetic: a meta-analysis. | 2002-05-02 |
|
| Intravenous regional blocks with guanethidine and prilocaine combined with physiotherapy: two children with complex regional pain syndrome, type 1. | 2002-05 |
|
| The effects of age on neural blockade and hemodynamic changes after epidural anesthesia with ropivacaine. | 2002-05 |
|
| [Management of leg ulcers in the elderly]. | 2002-04 |
|
| Intravenous regional guanethidine blockade in the treatment of post-traumatic complex regional pain syndrome type 1 (algodystrophy) of the hand. | 2002-04 |
|
| Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. | 2002-04 |
|
| Lidocaine-prilocaine cream versus tetracaine gel for procedural pain in children. | 2002-04 |
|
| EMLA cream-induced irritant contact dermatitis. | 2002-03 |
|
| Topical anesthesia for minor gynecological procedures: a review. | 2002-03 |
|
| Subcutaneous infusion anesthesia for dermatologic surgery in children: are we ready? | 2002-02-14 |
|
| Dermatosurgery using subcutaneous infusion anesthesia with prilocaine and ropivacaine in children. | 2002-02-14 |
|
| Effects of dental local anaesthetics in cardiac transplant recipients. | 2002-02-09 |
|
| EMLA cream prior to digital nerve block for ingrown nail surgery does not reduce pain at injection of anesthetic solution. | 2002-02 |
|
| A comparison of prilocaine and lidocaine for intravenous regional anaesthesia for forearm fracture reduction in children. | 2002-02 |
|
| [Tumescent technique for local anesthesia]. | 2002-02 |
|
| Vascular and neural mechanisms of ACh-mediated vasodilation in the forearm cutaneous microcirculation. | 2002-02 |
|
| Reader questions pain and peritumoral injection. | 2002-01-31 |
|
| Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. | 2002-01-31 |
|
| Evidence that the human cutaneous venoarteriolar response is not mediated by adrenergic mechanisms. | 2002-01-15 |
|
| Use of negatively charged cyclodextrins for the simultaneous enantioseparation of selected anesthetic drugs by capillary electrophoresis-mass spectrometry. | 2002-01-15 |
|
| Local anesthesia prior to the insertion of peripherally inserted central catheters. | 2002-01-05 |
|
| Local anesthesia with EMLA cream for maxillary sinus puncture. | 2002-01 |
|
| Topical anesthetics update: EMLA and beyond. | 2001-12 |
|
| The tumescent facial block: tumescent local anesthesia and nerve block anesthesia for full-face laser resurfacing. | 2001-12 |
|
| [Some aspects of epidural anesthesia in patients with chronic renal insufficiency]. | 2001-11-06 |
|
| [Can treatment of flat angiomas be proposed in the first months of life?]. | 2001-11 |
|
| Efficacy of subcutaneous and topical local anaesthesia for pain relief after resection of malignant breast tumours. | 2001-11 |
|
| A randomized double-blind, placebo-controlled trial of the EMLA patch for the reduction of pain associated with intramuscular injection in four to six-year-old children. | 2001-11 |
|
| Blood flow changes in human dental pulps when capsaicin is applied to the adjacent gingival mucosa. | 2001-11 |
|
| Pain experience during transvaginal aspiration of immature oocytes. | 2001-11 |
|
| Reflection spectroscopy of analgesized skin. | 2001-11 |
|
| Quality of anaesthesia for insertion of tension-free vaginal tape using local analgesia and sedation. | 2001-11 |
|
| [Neurotoxicity of intrathecal lidocaine]. | 2001-10-10 |
|
| Plasma concentrations of lignocaine and prilocaine after a 24-h application of analgesic cream (EMLA) to leg ulcers. | 2001-10 |
|
| Pain on injection of prilocaine plain vs. lidocaine with epinephrine. A prospective double-blind study. | 2001-10 |
|
| [New uses of EMLA: anesthesia for relief of pain caused by hemorrhoid thrombosis]. | 2001-10 |
|
| [Ovarian puncture in fertilization in vitro: what analgesia?]. | 2001-09 |
|
| The effect of lidocaine/prilocaine cream on an experimental wound healing model. | 2001-09 |
|
| From cocaine to ropivacaine: the history of local anesthetic drugs. | 2001-08 |
|
| Topical anesthetics in children: agents and techniques that equally comfort patients, parents, and clinicians. | 2001-08 |
|
| 1% lidocaine injection, EMLA cream, or "numby stuff" for topical analgesia associated with peripheral intravenous cannulation. | 2001-06 |
|
| Use of EMLA: is it an injection free alternative? | 2001 |
|
| [Experiences with liposuction of established surgeons]. | 2001 |
|
| Noninvasive drug delivery. | 2001 |
Sample Use Guides
Use the included blunt tipped applicator to apply gel to gingival margins and periodontal pockets
Route of Administration:
Dental
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11421833
Prilocaine inhibited FMLP-induced CL in human leucocytes (94+/-1%, at 1 mM). In cell-free experiments, prilocaine (22+/-6%, at 1 mM) caused concentration-dependent inhibition in xanthine-xanthine oxidase-induced CL.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:02 GMT 2025
by
admin
on
Mon Mar 31 18:02:02 GMT 2025
|
| Record UNII |
MJW015BAPH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID2031956
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
MJW015BAPH
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL1194
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
DBSALT000962
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
92163
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
MJW015BAPH
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
32053
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
217-244-0
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
m9132
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
1786-81-8
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
1561008
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
SUB04038MIG
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
C48012
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
100000085080
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
758432
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | |||
|
2557
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
88208-29-1
Created by
admin on Mon Mar 31 18:02:03 GMT 2025 , Edited by admin on Mon Mar 31 18:02:03 GMT 2025
|
SUPERSEDED |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |